血管紧张素受体拮抗剂治疗高血压

肾素-血管紧张素-醛固酮系统（RAAS）是调节血压的主要机制，也是治疗高血压病的重要靶点。血管紧张素受体拮抗剂（ARBs），通过阻滞特异性血管紧张素受体，干扰RAAS的活性，成为治疗高血压的一线药物。临床结果显示ARBs作为单用药或联合其他降压药物治疗高血压有其特殊的优势。在降压方面，与血管紧张素转换酶抑制剂和其他类型的降压药物相比，ARBs具有良好的耐受性而适合用于治疗更广泛的患者。最近研究结果显示在12个月期间使用ARBs治疗高血压依从性明显高于其他降压药物，而且副作用少。具备临床有效性和良好耐受性的ARBs药物，可以作为治疗高血压的主要药物。

Angiotensin receptor blockers for management of hypertension

The renin-angiotensin-aldosterone system （RAAS） plays a major role in blood pressure regulation, and is thus an important therapeutic target in the management of hypertension. Angiotensin receptor blockers （ARBs）, which interrupt RAAS overactivity by blocking a specific receptor of angiotensin Ⅱ, act for the management of hypertension. Clinical evidence demonstrates that ARBs are effective in the management of hypertension as monotherapy or in combination with other agents. Although comparable to angiotensin-converting enzyme inhibitors and other major classes of antihypertensive agents in the treatment of hypertension, ARBs are attractive alternatives for many patients due to its favorable tolerability profile. Recent evidence suggests that treatment persistence with ARBs therapy during a 12-month period be typically higher than that with other antihypertensive classes, and fewer side effects are observed. The advantages of clinical efficacy and tolerability qualify the ARBs as major treatment alternatives for hypertension.